Skip to main content
. 2009 May 22;42(4):541–553. doi: 10.1111/j.1365-2184.2009.00609.x

Figure 4.

Figure 4

RT‐PCR analysis using specific primers for cyclin B1 and p34cdc2 mRNA expression (a and c) and Western blot analysis (b and d). (a and c) Top: Lane 1, untreated A375P cells mRNA; lane 2, mRNA from A375P treated with 80 µg/ml 3‐O‐methylfunicone (OMF) for 24 h; lane 3, untreated A375M cells mRNA; lane 4, mRNA from A375M treated with 80 µg/ml OMF for 24 h. M, 100‐bp ladder MW marker (Roche Diagnostics). Bottom: Quantitative measurements of the band intensities. (b and d) Lane 1, untreated A375P cells; lane 2, A375P treated with 80 µg/ml OMF for 24 h; lane 3, untreated A375M cells; lane 4, A375M treated with 80 µg/ml OMF for 24 h. Data shown are representative of five different experiments (± standard deviation). *Significantly different compared with control (P < 0.05).